Leukemia Home > Gleevec and Bleeding

During treatment with Gleevec® (imatinib mesylate), you may be at risk for abnormally low blood cell counts, such as low red blood cells, white blood cells, or platelets, which can increase your risk for anemia, infection, and bleeding problems.
 
Your healthcare provider will monitor your blood counts with a simple blood test every week for the first month you are taking Gleevec, every other week during the second month, and then periodically for the remainder of treatment. If you develop problems with bleeding, your healthcare provider may need to reduce your dose or temporarily stop treatment.
 
(To learn more about bleeding, edema, congestive heart failure, and other problems that may occur with this drug, click Gleevec Warnings and Precautions.)
 
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):
Advertisement
Topics

Medications

Quicklinks

Related Channels

eMedTV Links
Copyright © 2006-2019 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.